Effects of a ketamine metabolite on synaptic NMDAR function
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AP5 (50 μM) and ketamine (50 μM) produced a 90-100% reduction in charge transfer indicating that AP5 and ketamine are more potent at inhibiting NMDAR-mEPSCs relative to (2R,6R)-HNK.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Suzuki et al., 2017
In the citing paper
“NMDAR-mEPSCs were concentration-dependently and rapidly (within 10 minutes) attenuated by (2R,6R)-HNK with 10 μM having no effect and 50 μM producing an ~40% reduction in charge transfer.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Suzuki et al., 2017
In the citing paper
“At the synaptic level, eEF2K inhibition increases AMPAR-mediated miniature EPSC amplitudes and induces rapid synaptic scaling, closely matching the profile seen after ketamine or 2R,6R-HNK [146,149,150].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [150]
In the citing paper
“Suzuki et al. (2017) 129 recently confirmed that (2R,6R)-HNK does not functionally inhibit NMDAR-mEPSCs at 10 μM 129.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [129]
In the citing paper
“These authors also reported that at a higher concentration (50 μM), (2R,6R)-HNK induces a modest (~40%) inhibition of NMDAR-mEPSCs 129, which could result in off-target effects of this metabolite at high doses.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [129]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Self-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
THE ROUTE OF ABSORPTION OF INTRAPERITONEALLY ADMINISTERED COMPOUNDS
LUKAS, G., BRINDLE, S. D., & GREENGARD, P. (1971) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28988-1 · Cited by 388
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283
Self-citationGideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
Self-citationAtasoy, D., Ertunc, M., Moulder, K. L., Blackwell, J., Chung, C., Su, J., & Kavalali, E. T. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2432-08.2008 · Cited by 200
Self-citationMoaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176
Memantine binding to a superficial site on NMDA receptors contributes to partial trapping
Kotermanski, S. E., Wood, J. T., & Johnson, J. W. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.176297 · Cited by 92
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
“Specific HNK metabolites of ketamine, (2S,6S)-HNK, and (2R,6R)-HNK, derived from the metabolism of (S)-ketamine and (R)-ketamine, respectively, do not bind to or functionally inhibit the NMDAR at antidepressant-relevant concentrations (Morris et al., 2017; Suzuki et al., 2017; Zanos et al., 2017a), but do exert antide…”
BackgroundResultInfluentialMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
“Moreover, (2R,6R)-hydroxynorketamine, the ketamine metabolite reported to be NMDA receptor–independent (131) [but see (132)], directly binds to TrkB with an affinity comparable to that of ketamine, but clearly higher than its affinity to NMDA receptor, and this binding is lost in the Y433F TrkB mutants.”
Self-citationAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
“This mechanism of action has been replicated by some (58, 59) but not all (60) groups.”
Dendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464
Psychedelics reopen the social reward learning critical period
Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06204-3 · Cited by 358
“288), and LSD and ibogaine 4 weeks after pretreatment (p, normalized: t(35) = −2.”
BackgroundDuman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
“Interestingly, (2R,6R)-HNK, the enantiomer with the stronger antidepressant-like effects, is a less potent antagonist of NMDAR than ketamine itself (Moaddel et al., 2013; Zanos et al., 2016, 2017; Morris et al., 2017; Suzuki et al., 2017).”
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
Widman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
“While there are conflicting reports on HNK’s ability to block NMDARs, it seems to enhance glutamatergic transmission mediated by AMPARs, which is required for the antidepressant-like effects in mice (19, 20, 43).”
BackgroundInfluentialBDNF at the synapse: why location matters
Song, M., Martinowich, K., & Lee, F. S. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.144 · Cited by 198
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188
“(9) reported that (2R,6R)-HNK had no activity at NMDA receptors, but a recent study reported inhibition of NMDA receptor currents in hippocampal slices, albeit at a very high concentration of (2R,6R)-HNK (50 μM) (54).”
BackgroundTargeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders
Kavalali, E. T., & Monteggia, L. M. (2020) · Neuron · doi:10.1016/j.neuron.2020.05.015 · Cited by 179
“In agreement with the studies outlined above, we have shown ketamine-mediated blockade of NMDA receptors at rest deactivates eEF2 kinase, resulting in a reduction of eEF2 phosphorylation and desuppression of BDNF translation (Autry et al., 2011; Suzuki et al., 2017).”
BackgroundSelf-citationMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“the CA1 region of hippocampus [45] at a concentration that does not alter the NMDA-evoked responses in brain slices [45] or hippocampal cell cultures [107, 108].”
BackgroundResultGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
“Extrasynaptic NMDARs, primarily comprising heterotetramers containing GluN2B subunits, are tonically activated by low levels of ambient glutamate.”
BackgroundInfluentialLumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
“It has been debated, however, whether NMDAR inhibition, the mechanism proposed to underlie the antidepressant effects of ketamine, contributes to the antidepressant effects of (2R,6R)-HNK (14, 31, 32, 40).”
BackgroundLi, Y.-F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107494 · Cited by 170
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0400-x · Cited by 154
“(2R,6R)-HNK (50 μM) blocks NMDA receptors [92].”
Cavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
“It was proposed that some of the long-lasting pharmacological effects of ketamine are mediated by its metabolites in vivo.(51,58,61) In our in vitro preparations we did not find metabolites, supporting ketamine direct”
Background( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Antidepressant actions of ketamine engage cell-specific translation via eIF4E
Aguilar-Valles, A., De Gregorio, D., Matta-Camacho, E., Eslamizade, M. J., Khlaifia, A., Skaleka, A., Lopez-Canul, M., Torres-Berrio, A., Bermudez, S., Rurak, G. M., et al. (2021) · Nature · doi:10.1038/s41586-020-03047-0 · Cited by 144
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 148
Self-citationPham, T. H., Defaix, C., Xu, X., Deng, S.-X., Fabresse, N., Alvarez, J.-C., Landry, D. W., Brachman, R. A., Denny, C. A., & Gardier, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.020 · Cited by 131
AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
NMDAR-independent, cAMP-dependent antidepressant actions of ketamine
Wray, N. H., Schappi, J. M., Singh, H., Senese, N. B., & Rasenick, M. M. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0083-8 · Cited by 123
“have suggested a possible role of NMDAR antagonism for (2R,6R)-HNK, yet this remains controversial [35].”
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-22.2022 · Cited by 115
Sustained Effects of Rapidly Acting Antidepressants Require BDNF-Dependent MeCP2 Phosphorylation
Kim, J.-W., Autry, A. E., Na, E. S., Adachi, M., Björkholm, C., Kavalali, E. T., & Monteggia, L. M. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00868-8 · Cited by 113
Self-citationLateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine
Cui, Y., Hu, S., & Hu, H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.002 · Cited by 106
“Ketamine is an activity-dependent blocker that blocks calcium influx of NMDAR at open state [38].”
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 108
Dendritic Spine Elimination: Molecular Mechanisms and Implications
Stein, I. S., & Zito, K. (2018) · The Neuroscientist · doi:10.1177/1073858418769644 · Cited by 123
(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice
Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & Chaki, S. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0084-y · Cited by 105
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
“An increase of membrane excitability boosts Ca2+ influx through calcium-permeable channels including NMDARs and voltage-gated Ca2+ channels.”
BackgroundInfluentialChou, D., Peng, H.-Y., Lin, T.-B., Lai, C.-Y., Hsieh, M.-C., Wen, Y.-C., Lee, A.-S., Wang, H.-H., Yang, P.-S., Chen, G.-D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.033 · Cited by 104
“At antidepressant-relevant concentrations (approximately 10 mM), (2R,6R)-HNK does not functionally inhibit the NMDA receptor (Suzuki et al., 2017; Zanos et al., 2016, 2017), demonstrating that (2R,6R)-HNK exerts an antidepressant effect at physiologically relevant concentrations through an NMDA receptor inhibition-ind…”
Synaptic Mechanisms Regulating Mood State Transitions in Depression
Parekh, P. K., Johnson, S. B., & Liston, C. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-110920-040422 · Cited by 101
A Synaptic Locus for TrkB Signaling Underlying Ketamine Rapid Antidepressant Action
Lin, P.-Y., Ma, Z. Z., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109513 · Cited by 99
“Surface TrkB Biotinylation Assay— Mouse hippocampal cultures were treated on DIV 14 with ketamine (50 μM) as described previously ( Suzuki et al., 2017) for two hours to match the time point of the antidepressant effects observed in the FST.”
Self-citationKetamine treatment for refractory anxiety: A systematic review
Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15374 · Cited by 104
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000149 · Cited by 92
“Although some data indicate that high concentrations of (2R,6R)-HNK (50 mM) partially inhibit miniature NMDAR-mediated currents (Suzuki et al., 2017), there is evidence to suggest that NMDAR blockade does not underlie the behavioral effects of (2R,6R)-HNK. (2R,6R)-HNK blocks NMDAR-mediated synaptic…”
BackgroundMethodResultInfluentialKetamine: Neuroprotective or Neurotoxic?
Choudhury, D., Autry, A. E., Tolias, K. F., & Krishnan, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.672526 · Cited by 82
Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2
Lopez, J. P., Lücken, M. D., Brivio, E., Karamihalev, S., Kos, A., De Donno, C., Benjamin, A., Yang, H., Dick, A. L. W., Stoffel, R., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.05.001 · Cited by 79
“, 2016), whereas others using higher concentrations ( 20 mM) have shown that ketamine and HNK can elicit relevant physiological, molecular, and electrophysiological effects in vitro (Kang et al., 2020; Lazarevic et al., 2021; Riggs et al., 2020; Suzuki et al., 2017).”
Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b02177 · Cited by 83
Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
Kalmoe, M. C., Janski, A. M., Zorumski, C. F., Nagele, P., Palanca, B. J., & Conway, C. R. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116778 · Cited by 74
Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 73
“However Suzuki et al. (2017) recently demonstrated that (2 R ,6 R )-HNK inhibits synaptic NMDARs, triggering the same signaling pathways activated by ketamine (i.e., decreased eEF2 phosphorylation) and proposing that the sustained inhibition of NMDARs by (2 R ,6 R )-HNK can explain the long-lasting…”
BackgroundHofstetter, R. K., Fassauer, G. M., & Link, A. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.01.024 · Cited by 77
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile
Johnston, J. N., Greenwald, M. S., Henter, I. D., Kraus, C., Mkrtchian, A., Clark, N. G., Park, L. T., Gold, P. W., Zarate, C. A., & Kadriu, B. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103518 · Cited by 80
Chen, B. K., Luna, V. M., LaGamma, C. T., Xu, X., Deng, S., Suckow, R. F., Cooper, T. B., Shah, A., Brachman, R. A., Mendez‐David, I., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0714-z · Cited by 71
What Acute Stress Protocols Can Tell Us About PTSD and Stress-Related Neuropsychiatric Disorders
Musazzi, L., Tornese, P., Sala, N., & Popoli, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00758 · Cited by 76
“The NMDA receptor-independent action of HNK has been questioned (Suzuki et al., 2017).”
BackgroundRiggs, L. M., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E. X., Pereira, E. F. R., Thompson, S. M., & Gould, T. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0443-3 · Cited by 66
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
Rodent ketamine depression-related research: Finding patterns in a literature of variability
Polis, A. J., Fitzgerald, P. J., Hale, P. J., & Watson, B. O. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112153 · Cited by 67
Kadriu, B., Musazzi, L., Johnston, J. N., Kalynchuk, L. E., Caruncho, H. J., Popoli, M., & Zarate, C. A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.027 · Cited by 62
Ponton, E., Turecki, G., & Nagy, C. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab082 · Cited by 65
Kohtala, S., Theilmann, W., Rosenholm, M., Penna, L., Karabulut, G., Uusitalo, S., Järventausta, K., Yli-Hankala, A., Yalcin, I., Matsui, N., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1364-6 · Cited by 60
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Self-citationLavender, E., Hirasawa-Fujita, M., & Domino, E. F. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112631 · Cited by 58
Rapid homeostatic plasticity and neuropsychiatric therapeutics
Kavalali, E. T., & Monteggia, L. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01411-4 · Cited by 55
“Here, as mentioned previously, resting NMDA receptor activity driven by spontaneous release has received particular attention as it is primarily targeted by ketamine and other NMDA receptor blockers to trigger rapid antidepressant action [10, 11, 51].”
BackgroundSelf-citationUncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Xu, S., Yao, X., Li, B., Cui, R., Zhu, C., Wang, Y., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740996 · Cited by 56
“High dose of (2R,6R)-HNK only partially impaired NMDAR-miniature excitatory postsynaptic currents (mEPSCs) (Suzuki et al., 2017), and the efficacy of (2R,6R)-HNK to displace NMDAR antagonist MK-801 is low.”
BackgroundThe role of eEF2 kinase in the rapid antidepressant actions of ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.005 · Cited by 52
Self-citationLack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model
Zhang, K., Fujita, Y., & Hashimoto, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-22449-9 · Cited by 49
Suzuki, K., Kim, J.-W., Nosyreva, E., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109918 · Cited by 49
Self-citationTargeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
“( 2R , 6R )-HNK has been found to initiate its rapid antidepressant-relevant effects through an NMDAR-independent mechanism and has completed phase I clinical trials (ClinicalTrials.gov Identi fi er: NCT04711005) [46, 47, 169 – 172].”
Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain
Kroin, J. S., Das, V., Moric, M., & Buvanendran, A. (2019) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2018-000013 · Cited by 49
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Bonaventura, J., Gomez, J. L., Carlton, M. L., Lam, S., Sánchez‐Soto, M., Morris, P. J., Moaddel, R., Kang, H. J., Zanos, P., Gould, T. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01673-w · Cited by 49
“also tested (2R,6R)-HNK at a higher concentration (50 μM) which led to a ~40% reduction in synaptic NMDAR currents [59].”
BackgroundEvaluation of in vitro neuronal platforms as surrogates for in vivo whole brain systems
Belle, A. M., Enright, H. A., Sales, A. P., Kulp, K. S., Osburn, J. J., Kuhn, E. A., Fischer, N. O., & Wheeler, E. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-28950-5 · Cited by 52
1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances
Wallach, J. V., & Brandt, S. D. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_148 · Cited by 50
Prophylactic efficacy of 5-HT4R agonists against stress
Chen, B. K., Mendez‐David, I., Luna, V. M., Faye, C., Gardier, A. M., David, D. J. P., & Denny, C. A. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0540-3 · Cited by 46
Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity
Schwenk, E. S., Pradhan, B., Nalamasu, R., Stolle, L., Wainer, I. W., Cirullo, M., Olson, A., Pergolizzi, J. V., Torjman, M. C., & Viscusi, E. R. (2021) · Current Pain and Headache Reports · doi:10.1007/s11916-021-00977-w · Cited by 47
Engaging homeostatic plasticity to treat depression
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.225 · Cited by 47
The impact of sex as a biological variable in the search for novel antidepressants
Williams, A. V., & Trainor, B. C. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.05.003 · Cited by 40
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 45
“In addition, Susuki and colleagues reported that a high concentration of 2R,6R-HNK (50μM) does not act on NMDARs, and its effect on neurotransmission and known intracellular signaling are not mediated via NMDAR blockade [100].”
BackgroundAntidepressant mechanisms of ketamine: Focus on GABAergic inhibition
Lüscher, B., Feng, M., & Jefferson, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.002 · Cited by 45
Vranjkovic, O., Winkler, G. A., & Winder, D. G. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0102-0 · Cited by 43
Collo, G., Cavalleri, L., Chiamulera, C., & Merlo Pich, E. (2018) · NeuroReport · doi:10.1097/wnr.0000000000001131 · Cited by 37
Fortress, A. M., Smith, I. M., & Pang, K. C. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.009 · Cited by 38
“Moreover, the long-term activation of AMPA receptors may be necessary and sufficient for the antidepressant actions of ketamine (Zanos et al., 2016; Suzuki et al., 2017).”
BackgroundYe, L., Ko, C.-Y., Huang, Y., Zheng, C., Zheng, Y., & Chou, D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107667 · Cited by 34
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2017) · Nature · doi:10.1038/nature22085 · Cited by 34
Morris, P. J., Burke, R. D., Sharma, A. K., Lynch, D. C., Lemke-Boutcher, L. E., Mathew, S., Elayan, I., Rao, D. B., Gould, T. D., Zarate, C. A., et al. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.106993 · Cited by 36
Amat-Foraster, M., Jensen, A. A., Plath, N., Herrik, K. F., Celada, P., & Artigas, F. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.022 · Cited by 36
“, 2016) although a very recent study indicates that HNK also blocks synaptic NMDA-R function (Suzuki et al., 2017).”
Ketamine – A New Antidepressant Drug with Anti-Inflammatory Properties
Jóźwiak-Bębenista, M., Sokołowska, P., Wiktorowska‐Owczarek, A., Kowalczyk, E., & Sienkiewicz, M. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001823 · Cited by 39
Novel psychotherapeutics – a cautiously optimistic focus on Hallucinogens
Sherwood, A. M., & Prisinzano, T. E. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1415755 · Cited by 35
“While the aforementioned hallucinogens tend to involve an element of guidance, introspection, and self-discovery associated with their positive clinical outcomes, ketamine may work through a less subjective, more biochemically driven ‘reset’ type of mechanism [16].”
BackgroundTse, Y. C., Lopez, J., Moquin, A., Wong, S.-M. A., Maysinger, D., & Wong, T. P. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0325-8 · Cited by 32
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
Lewis, V., Rurak, G. M., Salmaso, N., & Aguilar‐Valles, A. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2023.12.004 · Cited by 33
A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action
Kim, J., Herz, J., Kavalali, E. T., & Monteggia, L. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103079118 · Cited by 30
Self-citationFattore, L., Piva, A., Zanda, M. T., Fumagalli, G. F., & Chiamulera, C. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4793-4 · Cited by 29
“…that the ketamine active metabolite 2R,6R-hydroxynorketamine (HNK) induces antidepressant effects via direct AMPA receptor agonism, suggesting an NMDAR-independent mechanism of action for this metabolite (Zanos et al. 2016; however, see recent Suzuki et al. 2017 and reply by Zanos et al. 2017).”
BackgroundKavalali, E. T., & Monteggia, L. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.210 · Cited by 29
“…experiments, we showed that 2R,6R-HNK can swiftly inhibit NMDAR transmission up to 50% at concentrations needed to trigger the intracellular signaling pathway involved in the potentiation of synaptic AMPAR responses, strongly supporting a role for NMDARblockade in this effect (Suzuki et al, 2017).”
BackgroundSelf-citationPharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine
Shaffer, C. L., Dutra, J. K., Tseng, W. C., Weber, M. L., Bogart, L. J., Hales, K., Pang, J., Volfson, D., am Ende, C. W., Green, M. E., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.019 · Cited by 28
Highland, J. N., Morris, P. J., Konrath, K. M., Riggs, L. M., Hagen, N. R., Zanos, P., Powels, C. F., Moaddel, R., Thomas, C. J., Wang, A. Q., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00761 · Cited by 28
Kawatake-Kuno, A., Murai, T., & Uchida, S. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.749180 · Cited by 28
Li, Y., Du, Y., Wang, C., Lu, G., Sun, H., Kong, Y., Wang, W., Lian, B., Li, C., Wang, L., et al. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100503 · Cited by 29
How could N-Methyl-D-Aspartate Receptor Antagonists Lead to Excitation Instead of Inhibition?
Su, T., Lu, Y., Geng, Y., Lü, W., & Chen, Y. (2018) · Brain Science Advances · doi:10.26599/bsa.2018.2018.9050009 · Cited by 27
“[157] has reported that slightly higher concentration of (2R,6R)‐HNK can significantly impair NMDAR function at rest in hippocampal slices and deactivates eEF2K, eliciting AMPAR‐dependent synaptic potentiation to produce the anti‐depression effect.”
BackgroundKohtala, S., Theilmann, W., Rosenholm, M., Müller, H. K., Kiuru, P. S., Wegener, G., Yli‐Kauhaluoma, J. T., & Rantamäki, T. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107684 · Cited by 29
“critical role of NMDAR antagonism as the main mechanism of ketamine's action, and has subsequently raised important debate about the neuropharmacological mechanisms involved (Collingridge et al., 2017; Suzuki et al., 2017).”
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2017) · Chronic Stress · doi:10.1177/2470547017743511 · Cited by 20
“almost 100% with 50 mM ketamine), and only this higher dose was found to induce a decrease in eEF2 kinase phosphorylation.(16) Based on these results, they conclude that similar to its parent compound, (2R,6R)-HNK is an open-channel NMDAR antagonist, which converges onto the same intracellular signalling pathways prev…”
BackgroundResultInfluentialSex differences in sub-anesthetic ketamine's antidepressant effects and abuse liability
Wright, K. N., & Kabbaj, M. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2018.02.001 · Cited by 23
Hofstetter, R. K., Potlitz, F., Schulig, L., Kim, S., Hasan, M., & Link, A. (2019) · Molecules · doi:10.3390/molecules24101927 · Cited by 21
Lewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
“Interestingly, (2R,6R)HNK, the enantiomer with the stronger antidepressantlike effects, is a less potent antagonist of NMDAR than ketamine itself (Moaddel et al., 2013; Morris et al., 2017; Suzuki et al., 2017; Zanos et al., 2016; Zanos et al., 2017).”
Background
Metadata
- Authors
- Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Monteggia, Lisa M.
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7659
- Pages
- E1-E3
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2631673659
- Cited by
- 180
- References
- 13
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 10 · 2023: 11 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 36 · 2017: 15
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine metabolites, hydroxynorketamine, NMDA receptor, synaptic plasticity, antidepressant effects, depression, rapid antidepressant response, spontaneous neurotransmission, glutamate release, memantine, age dependence, intraperitoneal administration, synaptic potentiation, depression biomarkers, depression remission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.